SCHEMBL8552263

SCHEMBL8552263

O=C1CC(S(=O)(=O)Cc2ccccc2)N1CCCCCCc1ccccn1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 1/20 0.39
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 1/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2D6 P10635 1/20 0.36
CYP1A2 P05177 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
NAAA Q02083 2/20 0.35
MAPT P10636 1/20 0.35
LMNA P02545 1/20 0.34
CACNA1B Q00975 2/20 0.34
ACHE P22303 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8439355 0.86 GSK3A (0.44) ALDH1A1CYP2C19CYP2D6CYP1A2SMN1; SMN2
SCHEMBL8623161 0.84 GSK3B (0.39) ALDH1A1HSD17B10SMN1; SMN2KMT2ANAAA
SCHEMBL8590402 0.83 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2KMT2AMAPTLMNA
SCHEMBL8772454 0.80 POLB (0.42) ALDH1A1KMT2ALMNA
SCHEMBL8772449 0.80 CYP1A2 (0.42) ALDH1A1CYP2C19CYP2D6CYP1A2KMT2A
SCHEMBL8550864 0.73 HDAC1 (0.39) HRH1RAB9AKMT2ALMNA
SCHEMBL8442243 0.69 TRPV1 (0.49) ALDH1A1SMN1; SMN2KMT2ALMNA
SCHEMBL8772533 0.68 KCNA5 (0.42) ALDH1A1CYP2C19SMN1; SMN2KMT2AMAPT
SCHEMBL12040591 0.68 HRH1 (0.67) HRH1ALDH1A1CYP2C19CYP2D6CYP1A2
SCHEMBL8440706 0.68 HMOX1 (0.40) ALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0865429-A1 AZETIDINONE COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1998-09-23 EP disclosed
WO-1997021676-A1 AZETIDINONE COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1997-06-19 WO disclosed